Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News MoonLake Immunotherapeutics MLTX

Healthcare Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MLTX)

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

GlobeNewswire 11 days ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

GlobeNewswire February 10, 2026

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

GlobeNewswire February 2, 2026

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

GlobeNewswire January 8, 2026

Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025

ACCESS Newswire December 15, 2025

Pomerantz LLP Reminds Shareholders with Losses on their Investment in MoonLake Immunotherapeutics - MLTX

ACCESS Newswire December 15, 2025

Contact Levi & Korsinsky by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics(MLTX)

GlobeNewswire December 15, 2025

MLTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTX

ACCESS Newswire December 15, 2025

Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by MoonLake Immunotherapeutics

ACCESS Newswire December 15, 2025
View More News ››

Opinion & Analysis (NDAQ:MLTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MLTX)

RE:MLTX....Bad NR and results....Fried on Monday open

Make note of the date and time of the NR......Retail never had a chance to get out. Only anyone capable of trading during the PM open at...
Iseneschal - September 29, 2025

MLTX....Bad NR and results....Fried on Monday open

  MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program...
Iseneschal - September 29, 2025
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. together with its subsidiaries, engages in the acquisition, exploration, and development of uranium ...
View More »

Podcasts